Oral Taxane Soft Capsule Formulation via Composite Solubilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating taxanes for oral administration in high concentrations is challenging due to low bioavailability and precipitation issues in conventional formulations, which affects the stability and efficacy of taxane-containing soft capsules.
Innovation Solution
Incorporating polyoxyl glyceryl fatty acid ester into the formulation with taxanes, medium chain triglycerides, monooleoyl glycerol, and surfactants to create a clear solution that can be filled into soft capsules without precipitation, using specific weight ratios and organic solvents for dissolution and removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If taxane is contained in high concentration (4% by weight or more) according to conventional formulation methods, then the capsule size can be reduced and patient compliance improved, but the taxane precipitates from the lipid solution and bioavailability decreases
Solution Approach 1:
The patent uses a composite solubilization system combining three components: medium chain triglyceride (lipid phase), monoglyceride (surface-active agent), and polyoxyl glyceryl fatty acid ester (solubilizer). This composite material system enables high concentration taxane dissolution without precipitation, resolving the contradiction between concentration and stability. The specific combination creates a synergistic effect where each component contributes to maintaining taxane solubility at high concentrations.
Solution Approach 2:
The patent optimizes the weight ratios of the three solubilizing components within specific ranges: medium chain triglyceride (40-70%), monoglyceride (5-30%), and polyoxyl glyceryl fatty acid ester (5-30%). By adjusting these parameters within defined boundaries, the formulation maintains taxane solubility and prevents precipitation while achieving high concentration (4% or more), thus resolving the stability-concentration contradiction.
2Ease of operation
If taxane is formulated for oral administration to improve patient compliance, then injection-related problems are reduced, but oral bioavailability remains very low due to efflux pump action and poor absorption
Solution Approach 1:
The patent employs monoglyceride and polyoxyl glyceryl fatty acid ester as intermediary substances that facilitate taxane absorption across the intestinal barrier. These intermediaries enhance mucoadhesive properties and promote lymphatic transport, bypassing the efflux pump mechanism that normally limits oral bioavailability. The intermediaries act as carriers that enable reliable oral delivery while maintaining patient compliance benefits.
Solution Approach 2:
The patent utilizes the lipid-based formulation system to exploit lymphatic transport pathways, effectively using the body's natural fluid transport systems to overcome absorption barriers. The medium chain triglyceride and associated solubilizers facilitate incorporation into chylomicrons, enabling transport via the lymphatic system rather than direct blood absorption, thereby avoiding hepatic first-pass metabolism and efflux pump action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for the formulation of taxane-containing soft capsules with high concentration taxanes, enhancing bioavailability and stability by preventing precipitation, thus improving patient compliance and therapeutic effectiveness.
Implementation Method 1
when formulation processes are performed by adding polyoxyl glyceryl fatty acid ester additionally to the conventional paclitaxel-containing compositions, a clear solution containing a taxane in a high concentration can be obtained
Implementation Method 2
bioavailability is increased through high mucoadhesive property in the intestine by the monoglyceride such as monoolein
Implementation Method 3
dissolving paclitaxel, along with a medium chain triglyceride, a monoglyceride, and surfactant, in an organic solvent
Data Source
AI summary
The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.